Xylem Inc. Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net
Xylem Inc. (XYL) reported Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net of $0 for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-25.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet · last filed 2013-02-25
- Xylem Inc. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2012-12-31 was $0.00.
- Xylem Inc. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2012-09-30 was $0.00.
- Xylem Inc. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2011-12-31 was $0.00.
- Xylem Inc. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2011-09-30 was $0.00.
- Xylem Inc. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2012 was $0.00.
- Xylem Inc. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2011 was $0.00.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 3 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 6 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 9 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 12 month |
|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-02-25 | $0.00 derived: sum of 2 quarters · filed 2013-02-25 | $0.00 10-K · filed 2013-02-25 | |
| 2012-09-30 | $0.00 10-Q/A · filed 2012-11-06 | $0.00 10-Q/A · filed 2012-11-06 | ||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-02-25 | $0.00 derived: sum of 2 quarters · filed 2013-02-25 | $0.00 10-K · filed 2013-02-25 | |
| 2011-09-30 | $0.00 10-Q/A · filed 2012-11-06 | $0.00 10-Q/A · filed 2012-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ITT INC. (ITT) | United States | $19.129B | 39.62 |
| IDEX CORP /DE/ (IEX) | United States | $16.848B | 32.33 |
| GRACO INC (GGG) | United States | $12.488B | 23.77 |
| FLOWSERVE CORP (FLS) | United States | $9.667B | 25.54 |
| GORMAN RUPP CO (GRC) | United States | $1.969B | 38.90 |
| AMPCO PITTSBURGH CORP (AP) | United States | $0.179B | -3.00 |